menu search

Context therapeutics announces poster presentation at upcoming 2022 asco annual meeting

Context Therapeutics (NASDAQ:CNTX) Inc has told investors that an abstract on the results of the monotherapy...

May 5, 2022, 10:02 am

Atreca: biotech with promise based on first candidate atrc-101

Preliminary evidence shows that ATRC-101 helps those patients with higher target expression; 8 out of 12 patients (66%) who took ATCR-101 with H-score...

April 22, 2022, 1:14 pm

Repare therapeutics shares dip after updated rp-3500 data in solid tumors

Repare Therapeutics Inc (NASDAQ: RPTX) presented updated data from its ongoing Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synt...

April 12, 2022, 9:48 am

Rubius shares plunge after early data from rtx-240 solid tumor trial

Rubius Therapeutics Inc (NASDAQ: RUBY) has announced updated data from the ongoing monotherapy Phase...

April 8, 2022, 2:19 pm

Clovis oncology's rubraca significantly improves pfs in ovarian cancer regardless of biomarker status

Clovis Oncology Inc (NASDAQ: CLVS) announced positive topline data from the monotherapy arm of Phase...

March 31, 2022, 9:34 am

Global blood therapeutics' oxbryta scores european approval for sickle cell disease

The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell...

February 16, 2022, 9:41 am

Global blood therapeutics' oxbryta scores european approval for sickle cell disease

The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell...

February 16, 2022, 9:41 am

Global blood therapeutics' oxbryta scores european approval for sickle cell disease

The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell...

February 16, 2022, 9:41 am

Sierra oncology: plenty of room to trade higher after latest myelofibrosis data

Positive results achieved in Phase 3 MOMENTUM study using momelotinib monotherapy for the treatment of ...

January 26, 2022, 5:11 pm

Sierra oncology: plenty of room to trade higher after latest myelofibrosis data

Positive results achieved in Phase 3 MOMENTUM study using momelotinib monotherapy for the treatment of ...

January 26, 2022, 5:11 pm

Sierra oncology: plenty of room to trade higher after latest myelofibrosis data

Positive results achieved in Phase 3 MOMENTUM study using momelotinib monotherapy for the treatment of ...

January 26, 2022, 5:11 pm

Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients

Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose i...

January 21, 2022, 12:14 pm

Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients

Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose i...

January 21, 2022, 12:14 pm

Mirati therapeutics posts 41% objective response rate in pretreated gi cancer patients

Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose i...

January 21, 2022, 12:14 pm

Nuvation (nuvb) gets fda clearance for oncology candidate

Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination wi...

January 21, 2022, 11:35 am

Nuvation (nuvb) gets fda clearance for oncology candidate

Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination wi...

January 21, 2022, 11:35 am

Nuvation (nuvb) gets fda clearance for oncology candidate

Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination wi...

January 21, 2022, 11:35 am

Sqz biotechnologies' cell therapy shows favorable safety profile in hpv+ solid tumors

SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy ...

December 2, 2021, 1:31 pm

Sqz biotechnologies' cell therapy shows favorable safety profile in hpv+ solid tumors

SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy ...

December 2, 2021, 1:31 pm

Sqz biotechnologies' cell therapy shows favorable safety profile in hpv+ solid tumors

SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy ...

December 2, 2021, 1:31 pm


Search within

Pages Search Results: